Insmed Incorporated

INSM

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 14, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.	Phase 3	Pseudomonas Aeruginosa Infection	-
Brensocatib 25 mg	Phase 3	Non-Cystic Fibrosis Bronchiectasis	-
Treprostinil Palmitil Inhalation Powder	Phase 3	Pulmonary Hypertension	-
LAI 590 mg	Phase 3	NTM Lung Infection Due to MAC	-
Liposomal amikacin for inhalation	Phase 3	Cystic Fibrosis	-
ALIS	Phase 3	Mycobacterium Infections, Nontuberculous	-
Azithromycin	Phase 3	Mycobacterium Infections, Nontuberculous	-
LAI (Liposomal Amikacin for Inhalation) 590 mg	Phase 3	Mycobacterium Infections, Nontuberculous	-
Brensocatib 10 mg	Phase 2	Non-Cystic Fibrosis Bronchiectasis	-
Placebo	Phase 2	Cystic Fibrosis	-
rhIGF-I/rhIGFBP-3	Phase 2	Myotonic Dystrophy Type 1	-
Arikayce™	Phase 2	Cystic Fibrosis	-
ARIKACE™	Phase 2	Cystic Fibrosis	-
Cisplatin liposomal	Phase 2	Osteosarcoma Metastatic	-
Arikayce™ 560 mg	Phase 2	Cystic Fibrosis	-
Mometasone furoate nasal spray (MFNS)	Phase 2	Chronic Rhinosinusitis Without Nasal Polyps	-
Treprostinil Palmitil	Phase 2	Pulmonary Hypertension	-
280 mg Arikayce™	Phase 2	Bronchiectasis	-
Liposomal amikacin for inhalation (LAI)	Phase 2	Mycobacterium Infections, Nontuberculous	-
Brensocatib	Phase 2	Hidradenitis Suppurativa	-

Catalyst Timeline

2 upcoming, 0 past

⭐Phase 3Next

Mar 14, 2026Treprostinil Palmitil Inhalation Powder

Primary completion for Treprostinil Palmitil Inhalation Powder trial (NCT05649722) in Pulmonary Hypertension

Phase 2

May 22, 2026Brensocatib

Primary completion for Brensocatib trial (NCT06685835) in Hidradenitis Suppurativa

Regulatory Approvals

INSM News